Biohaven Ltd.
Biohaven Ltd. (BHVN) is a clinical-stage biopharmaceutical company advancing a diversified pipeline across neuroscience, immunology, oncology, and obesity, with notable year-to-date stock outperformance relative to the broader market despite being pre-revenue and experiencing substantial operating losses.
Summary based on data available as of July 2026 • All information subject to rapid change in biotech sector
Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for immunology, neuroscience, oncology, and obesity. The company maintains a broad pipeline of early- to late-stage candidates leveraging proprietary platforms such as Kv7 ion channel modulation, molecular degraders (MoDE/TRAP), and myostatin-activin pathway targeting. This diversified approach is viewed by some analysts as a strength for risk mitigation, though it also spreads resources across multiple high-risk programs.
Fact: Corporate history derived from SEC filings and company disclosures. The 2022 restructuring represents a key corporate event.
| 2026 (YTD) | +36.76% |
| 2025 | -69.77% |
| 2024 | -12.73% |
| 2023 | +208.36% |
Biohaven remains pre-commercial with zero reported revenue in recent periods. Operations are funded through equity raises and existing cash reserves.
| Metric (Annual) | Recent Periods (approx.) |
|---|---|
| Total Revenue | $0 |
| Operating Expenses | $436M – $885M range |
| Net Income (Loss) | -$408M to -$846M |
| Basic EPS | -$5.73 to -$12.75 |
Data Limitation: Financial figures drawn from Yahoo Finance, MarketWatch, and company reports (primarily 2024–2025 periods). Exact quarterly breakdowns vary; latest available data as of search (July 2026). High cash burn is typical for clinical-stage companies advancing multiple Phase 2/3 programs.
Analyst views range from bullish on pipeline breadth to cautious on cash burn and binary clinical outcomes. Recent actions include PT raises (e.g., Deutsche Bank) and occasional downgrades.
News aggregated from TipRanks, The Fly, company announcements. Clinical outcomes remain uncertain and binary in nature.
As a clinical-stage company with no approved commercial products, Biohaven has no traditional paying customers. Future revenue will depend on successful commercialization of pipeline candidates.
These represent IP licensing, manufacturing, or academic collaborations rather than customer relationships.
Primarily other clinical-stage biotechs in neuroscience, rare diseases, immunology, and oncology.